Maria Carmela Piccirillo, MD, discusses the safety profile of bevacizumab plus erlotinib in EGFR-mutated advanced nonsquamous non–small cell lung cancer.
Maria Carmela Piccirillo, MD
Advertisement
Articles by Maria Carmela Piccirillo, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
4
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
5